A shift in corporations’ motivations for adopting a captive as part of their risk management strategy makes a unified set of European rules for captives more attractive. That, in turn, reinforces the appeal of captives themselves, to create a rare circle of virtue.
In this GCP Short, produced in partnership with MAXIS Global Benefits Network, we explore findings from the network's latest whitepaper on GLP-1s, often known as weight-loss drugs.
